Researchers have identified the gene which affecting brain tumor development

Researchers at Cedars-Sinai have identified a stem cell regulatory gene that affects the growth of brain tumors and it can strongly affect patient survival. The findings involving recombinant human proteins are published in the online version of Scientific Reports, which will allow physicians to get closer to the goal: to better predict the prognosis of brain tumor patients and to develop more personalized treatments for them.

In order to enhance the understanding of how glioma stem cells (GCSCs) reproduce and how they affect patient survival, the researchers spent three years analyzing the genetic composition of more than 4,000 brain tumors. During their investigation, they identified genes that regulate tumor growth, and the gene is called ZEB1. Researchers' analysis showed that patients with brain cancer without this gene often had a lower survival rate.

"The cancer in patients who do not have this gene in the tumor is more aggressive and develops into an uncontrollable number of cell types," said Dr. John Yu, associate professor of neurosurgery oncology and deputy director of the Department of Neurosurgery. These new information can help us measure mutations in these patients so that we can provide more accurate prognosis and treatment plans.

When cancer cells (also known as malignant cells) appear in the brain tissue, brain cancer happens. This year, more than 23,000 people will suffer from primary cancerous tumor of brain. According to the National Cancer Institute and the American Cancer Society, about 16,000 of these patients will die.

Yu and colleagues have pointed out that although some brain cancer patients are born without this gene and others have, the gene has become less powerful over time - it may have a pathogenic effect.

"Compared with those with the gene, we found that the survival time was reduced by eight and a half months in patients with mild glioma with ZEB1 gene mutations," said Yu, co-chair of Cedars-Sinai Surgical Neuroinology. "We know that chemotherapy in some people with gene loss is ineffective, so we have to treat them with different drugs." Flarebio provides you with good-quality recombinant proteins including recombinant Nrg2 at competitive prices.

Scientists have found that stimulating immune system may stop tumor growth

According to a new study, the discovery of chemicals in tumors may help to prevent tumor growth. Researchers at the University of Illinois at Chicago report that the increase in chemical cytokines called LIGHT in mice with colon cancer activates the natural killer T cells of the immune system and causes contraction of metastatic tumors in primary tumors and liver. The LIGHT is an immunostimulating chemical messenger that was previously found to have low levels of expression in patients with colon cancer metastases. The results were published in Cancer Research which has published studies on various recombinant proteins including recombinant horse proteins.

Colon cancer is the second leading cause of cancer death in the United States. "The current treatment is palliative for most patients with colon cancer who have spread to the liver," said Dr. Ajay Maker, Associate Professor of Surgery at UIC Medical School. "Although studies suggest that immunotherapy may be a form of promising way to treat advanced cancer, this treatment has not been very successful for advanced gastrointestinal metastasis."

Maker and his colleagues established colon cancer tumors in the mouse model, in which animals had a complete and unedited immune system. Once the tumor size was visible, the mice were randomized into two groups - one group turned on cytokine LIGHT in the tumor and the other group was used as a control group for comparison.

"We have demonstrated that the delivery of therapeutic immunostimulatory cytokines results in the transport of T cells into the tumor and becomes activated tumor killer cells," said Maker. "This activity is particularly exciting because it leads to a deep anti-tumor immune response having no other chemotherapy or intervention, manipulating our natural defense system to combat the tumor."

"We have not only found that LIGHT expression promotes tumor regression, and after further studies we have also identified specific types of T cells responsible for contracting tumors," said Maker, "These findings are strong and have great clinical potential." By the way, Flarebio provides you with superior recombinant proteins such as recombinant Nrg2 at competitive prices.

Scientists have developed lower-cost therapy for uncommon genetic diseases

Scientists from an international research group suggested in Nature on Feb. 22 that blocking the molecules which cause Gauchers disease (GD) and other lysosomal storage disease (LSD) inflammation and organ damage can be used as a treatment, and this method is lower than the current treatment costs. More research through recombinant human proteins will be conducted.

Through the study of laboratory mouse models and human cells, the team showed that C5aR1 is a key molecular pathway in driving the inflammatory process of Goie disease. The process of inflammation of Geshe disease is initiated by the mutation of GBA1 gene. GBA1 encodes lysosomal enzyme glucocerebrosidase (GCase), which degrades the adipose molecule glucoamate (GC). C5aR1 is a small peptide (protein component) receptor from a complement system known as C5a (part of the immune system) that drives inflammation in several different types of immune cells.

Dr. Manoj Pandey, a scientist at the Syndicate Children's Human Genetics Division, and his colleagues showed that inflammatory glucose enamel accumulation in the spleen, liver, lung and bone marrow immune cells drives the self-expression of the glucose-ceramide that forms the immune complex antibody induction. These immune complexes promote the production of C5a and the activation of its receptor C5aR1.

Based on the evidence that C5aR1 participates in the process of Goie's disease, the researchers decided to test targeted molecular pharmacology in laboratory mouse models. Using C5aR antagonists (C5aRA) developed by K?hl, scientists injected C5aRA into the peritoneal cavity of mice. In the lung, liver and spleen of mice, the infiltration of proinflammatory immune cells (macrophages) is substantially reduced, and the accumulation of glucose-ceramide is almost completely eliminated.

Because the current project was carried out in mouse models and human blood cells, Pandey and his colleagues stressed the need for additional research before determining whether C5aR1 is effective and safe enough to be tested in human patients.

Pandey said the researchers will continue to test the C5aRA molecules used in mouse studies that are effective in targeting human and mouse C5aR. They will also test commercially available anti-C5 monoclonal antibodies called eculizumab and produced by Alexion Pharmaceuticals, which helped finance this study. This will allow researchers to test these compounds as a neoadjuvant therapy for human patients with Gaucher and other lysosomal storage diseases. Flarebio provides you with high-quality recombinant proteins such as recombinant Nrg2 at competitive prices.

New insights into further treatment options of cancer

A team from Yale University found through recombinant rat proteins that melanoma cells and white blood cells fuse to form a metastatic mixture. This finding further explains the spread of melanoma and other cancers, providing new insights into further treatment options.

When the malignant cells from a primary tumor spread to other tissues and organs, the cancer becomes deadly. The team analyzed tumor biopsies in patients with malignant melanoma who had undergone bone marrow transplants prior to cancer, comparing DNA from primary melanoma to lymph node DNA after cancer spread. In both cases, they found a mixture of the patient's own DNA and the donor's DNA.

The presence of this hybrid DNA is intense on the surface, which generally attacks cancer cells rather than fused leukocytes, forming a genetic mixture after diffusion.

These findings can serve as new cancer treatment targets. "We need to focus on how leukocytes and cancer cells fuse, and this process involves many steps. These steps are our goals. Future therapy can be designed to prevent bone marrow-derived fusion cells. These studies are focused on the new technology pathways of discovery of targeted metastasis itself," the researchers conclude. Flarebio offers high-quality recombinant proteins including recombinant Nrg2 at competitive prices.

Melanoma can be treated by interleukin-9 protein

US researchers found through research involving recombinant dog proteins that a protein has the efficacy of treating the skin cancer melanoma. This protein can be synthesized by the human body, so it is expected to develop new treatment to promote the body to fight against melanoma on this basis.

Melanoma is a malignant skin cancer, and the mortality rate is high. The researchers from Harvard University School of Medicine and other institutions conducted research on some melanoma patients with tissue samples and found that compared with normal levels, the patient code number for the interleukin-9 protein content is much lower or even missing.

The researchers also explored the effect of this protein on melanoma through animal experiments, and the results showed that if the mice injected with the inhibitory effect of interleukin-9 substances, the melanoma they suffer will grow rapidly, which is similar to human patients who have this protein in vivo.

However, if mice were injected with substances that promote an increase in their interleukin-9 levels, the rate at which they develop melanoma will decrease. This suggests that interleukin-9 is a protein that inhibits melanoma.

Interleukin-9 can achieve self-synthesis in the human and experimental mice, and we knew that it is a signal molecule which can mobilize the immune system in the past. The researchers suggested that in the future treatment of melanoma patients, it is suggested to promote the synthesis of more human interleukin-9 to mobilize the power of the immune system itself to inhibit tumor growth. Cusabio provides you with high-quality recombinant proteins such as recombinant Nrg2 at good prices.

The new inhibition function of NOX4 protein in liver cancer

Researchers at the Bellvitge Institute for Biomedical Research (IDIBELL) in collaboration with King's College London have revealed the role of NADPH oxidase NOX4 as an inhibitor of epithelial amebiasis. This process helps tumor cells migrate and invade. The study was recently published in the journal Oncogene, which also publishes other studies on recombinant human proteins.

In previous studies, the researchers suggested that NOX4 acts as a tumor suppressor in the liver by inhibiting cell proliferation. "In this work, we demonstrate that NOX4 is also an important inhibitor of the invasion and metastasis of liver tumor cells," explains Dr. Isabel Fabregat, leader of the IDIBELL study group.

In-vitro studies have shown that NOX4 silencing in liver tumor cells induces amoeba migration motility. Deformation motions associated with cell shrinkage are regulated by the Rho family of proteins, and the increased expression leads to this type of movement, which is associated with aggressive metastasis.

In patients with hepatocellular carcinoma, a large number of cases were observed in the absence of NOX4. In addition, those patients with lowly-expressed NOX4 and highly-expressed Rho protein had worse prognosis. "This translates our in-vitro studies into translational correlates because it brings new prognostic biomarkers for this type of cancer," said IDIBELL.

NOX4 is regulated at the transcriptional level of TGF-β cytokines, which has been studied by the group for 15 years. TGF-β is known to be a tumor suppressor at an early stage, but it becomes an inducer at an advanced stage. According to previous studies by this group, when the expression level of NOX4 was high, TGF-β showed as inhibitors, so the use of inhibition of TGF-β drugs would be counterproductive. This study suggests that this type of drug can be an ideal candidate for patients when NOX4 is expressed at low levels and the expression level of Rho protein is high. "Thus, lowly-expressed NOX4 can be used not only as a marker of poor prognosis, but also as a marker for the use of TGF-beta inhibitors," Dr. Fabregat concluded. Flarebio offers good-quality recombinant proteins like recombinant Nrg2 for your research.

Scientists find a protein that summons cell's gene-silencing machinery

It is known that organisms must defend themselves against parasitic genetic elements called transposons, from bacteria to humans, and the stake they undertake are high. These pieces of DNA jump around in the genome thus descripting genes. It can cause so much destruction that cells have dedicated surveillance mechanisms to keep them in check. Defects in these innate defense systems usually result in sterility. In animals, studies using recombinant horse proteins show that the main defense against troublemaking transposons is the Piwi-interacting RNA pathway.

In new research, scientists led by Cold Spring Harbor Laboratory (CSHL) Professor Gregory Hannon, who is also a Professor and Senior Group Leader at the CRUK Cambridge Institute at the University of Cambridge, have identified a protein the Piwi system uses to guide a cell's gene-silencing machinery to the right spots in the genome, allowing it to keep transposons inactive without interfering with the organism's own genes.

Scientists led by Cold Spring Harbor Laboratory (CSHL) Professor Gregory Hannon, who is also a Professor and Senior Group Leader at the CRUK Cambridge Institute at the University of Cambridge just conducted a new research, identifying a protein the Piwi system uses to guide a cell's gene-silencing machinery to the right spots in the genome, which allows it to keep transposons inactive and not interfere with the organism's own genes. They playfully named the protein Panoramix, after a comic book character who endows others with great power.

The Piwi-interacting RNA pathway, which is active in germline cells - those that give rise to sperm and eggs—is a double-tiered defense system. The most direct line of defense finds and chews up RNA copies of transposons, while a second mechanism finds transposons within the genome and tags them with chemical signals that instruct the cell to keep them safely off. The two modes of control provide the tightest possible clamp on the system.

The study of Hannon and his colleagues are currently focusing on the system that chemically tags transposon DNA. It happens as the elements are preparing to move, when transposon DNA is copied from its place in the genome into RNA, a process known as transcription.

According to Hannon, the Piwi system's challenge is to locate these sequences which look a lot like an organism's own genes, and tag them to make them be recognized by the same machinery a cell uses to switch its own genes off as needed. They think Piwi-interacting RNAs are responsible for finding transposons as RNA copies emerge, but the next was unknown. They hope to figure out the link between this very transposon-specific pathway to the more general repressive machinery of the cell.

They listed a lot of molecules which are possible to play this role and tested them. The Piwi system is so fast that they have found it nearly impossible to follow its components as they silence their natural targets. Later they constructed an artificial Piwi target, then stuck different components of the Piwi system to it and saw what was going on next.

For the most part, cells treated the piece of DNA that encoded the target as one of their own genes. However, when Panoramix was tethered to the artificial RNA target, it was able to halt transcription of the foreign piece of DNA. It means that once transcription began, Panoramix recruited the cell's gene silencing machinery to shut off local transcription and mark the intrusive DNA so that it would remain off, even in future generations.

It's a quite specific phenomenon. Panoramix summons the cell's gene-silencing machinery without affecting the activity of any of the fruit fly's own genes. The scientists believe that there may be a similar protein that plays the same role in humans and other animals. Flarebio provides good-quality recombinant proteins including recombinant Nrg2 for you.

Yoshinori Ohsumi finds the real autophagy mechanism

The Nobel Prize in Physiology or Medicine in 2016 was awarded to Yoshinori Ohsumi who is interested in recombinant human proteins, because he discovered the autophagy mechanism. This is an evolutionarily conserved process in which eukaryotic cells can be partly recirculated through transporting double membrane vesicle to lysosome. Unlike other mechanisms of cellular degeneration, autophagy can remove aged or damaged proteins, macromolecular complexes and organelles, leaving place for participation in new physiological processes. In addition, autophagy is also a key cellular process for the removal of invading microbes and toxic protein aggregates, which plays a key role in the fight against infection, aging, and many human diseases.

Although autophagy has been confirmed in the 1960s, scientists still have little knowledge of its mechanisms and physiological significance over the next few decades. The work of Yoshinori Ohsumi significantly changes the understanding of this important cellular process.

In 1993, Yoshinori Ohsumi published his groundbreaking in fifteen genes in the yeast. Subsequently, he cloned these genes in yeast and mammalian cells and elucidated the function of the coded protein. Based on the pioneering discovery of Yoshinori Ohsumi, the importance of autophagy in human physiology and diseases is now widely recognized. Flarebio offers recombinant proteins of good quality such as recombinant Nrg2.

Genome sequencing uncovers the adaptability of water bear in extreme environment

Water Bear is a small aquatic animal, also known as tardigrade. The issue of Nature - Communications published an article of latest research results on its genome sequence on September 20th. Through research using recombinant proteins, the study found that a kind of gene in the body of tardigrade, its protein can resist the DNA damage in human-cultured cells. This suggests that this protein which is specific for tardigrades may help cells to resist DNA damage sources.

Tardigrada can survive in extremely stressful environment (including vacuum), but scientists didn't know specifically how it survives in extreme environments. This ability of tardigrada prompted researchers to investigate its genome. The first genome sequencing results show that in the process of evolution of tardigrade, it obtains a large number of genes from other species by horizontal gene transfer (DNA transfer among genomes of different species). However, the rooted reason of tardigrada showing tolerance in extreme environment is still an unsolved mystery.

Takekazu Kunieda and colleagues at the University of Tokyo, Japan, presented to the high-quality genome of water bears which are known to tolerate high-pressure environment, and they found no evidence of large-scale horizontal gene transfer. But compared with flies and worms, the number of genes which are responsible for tolerating high-pressure environment was much more. In addition, they found a protein which binds to DNA and helps to protect cultured human cells from being affected by X-ray radiation, and they believed that the protein is unique for Tardigrada. Through a detailed comparison of tardigrada genes and genes from other species, the authors found that the gene designated as the genetic code of this protective protein may be specific to Tardigrada. These results don't support the viewpoint of the tolerance coming from horizontal gene transfer.

Although it remains unclear how tardigrada's unique adaptability play a role in the molecular level or organism level, the results of the study show that tardigrada has evolved and obtained unique "cheats" against high-pressure condition. Flarebio provides superior recombinant proteins such as recombinant Nrg2 at good prices.

British scientists have another viewpoint on cancer metastasis

Cancer metastasis is the process of cancer cells separating themselves from primary tumor and spreading to other parts of the body through the blood or lymphatic system. Once the cancer spreads, the treatment becomes more challenging. Chemotherapy, hormone therapy, radiation therapy and other therapies like recombinant human proteins can be successful in the treatment of some metastatic cancers, but for most metastatic cancers, the prognosis is poor.

Recently, early study of UK Queen Mary University of London (QMUL) found that cancer cells seem to depend on an unusual survival mechanism to spread throughout the body. This discovery could help to find a prevention and treatment method of metastasizing and secondary tumors in the future. The study is published in the journal Nature Communications. The researchers used mice and zebrafish to conduct research and tested the changes that occurred when cancer cells broke away from a tumor cell cluster. Researchers revealed an unknown survival mechanism of cancer cells in the past and found that a molecule called "integrins" may be the key through experiments using recombinant mouse proteins.

Integrins are proteins on the surface of cells, and they act with surrounding environment around the cells. Integrins are involved in "outside-in" and "inside-out" signaling and can help cancer cells be adhered to the surrounding environment. But the study found that when cancer metastasizes, integrins change to a new form of communication from adhesion function which is a signal "from within the inside". The integrins send signals within cells, which has never been found before.

The researchers found that an integrin called β1and another protein called c-Met paired up and went into the interior of the cell together with each other. These two proteins would enter in a specific site in the cell, and the role of this site is to degrade and recover cellular components. But in this case, the site is used for cell communication. These two proteins would send signals to other regions of the cell and trigger defense mechanisms of cell death in the transfer process.

Integrin inhibitor has been tested as a method for the treatment of cancer. Currently, the drug can targetedly act on the activity of integrin signaling on the surface of cancer cells. The researchers said this may explain why the efficacy of these drugs is so poor. A new strategy is to block integrin proteins from entering the cell. The researchers hope this viewpoint can help to design better treatments for cancer metastasis. Flarebio offers recombinant proteins of good quality including recombinant Nrg2 at reasonable prices.

Japanese scientists develop a new technology to analyze secondary structures of protein

The Joint Study Group of RIKEN and Japanese electronics companies announced on August 1st, 2016 that they successfully developed a nuclear magnetic resonance method (NMR method) which it is possible to analyze the secondary structure of protein without the use of isotopic label. The research involves many kinds of recombinant proteins like recombinant horse proteins.

Secondary structure of protein means that polypeptide chain of a protein has a conformation which repeated regulation, and it is the basis of overall shape of a protein. The representative secondary structure of protein is β-sheet which is composed of extended polypeptide chain and can be divided into two types: parallel and antiparallel type.

It has been demonstrated in previous studies that the abnormal deposition of β-amyloid is one of the pathogenesis of Alzheimer's disease, while the β-amyloid protein is rich in β- sheet configuration. Because β- sheet configuration is very messy, it is difficult to use X-ray diffraction and cryo-electron microsocopy to analyze. Further, since the β-amyloid is not insoluble in water, so it can't use the NMR assay solution. In order to analyze these types of proteins such as β-amyloid protein, it is needed to artificially increase the isotope-labeled sample of carbon isotope 13C and nitrogen isotope 15N to conduct solid MAS NMR. But because the natural existing rates of 13C and 15N are only 1.1% and 0.36%, so the range of use is very limited.

The research team previously used to develop ultra-small NMtR sample tube which can rotate sample at a high speed. The researchers also successfully developed 14N/14N-related NMR testing method which can obtain the space information among nitrogen isotope 14N atoms which have the isotopic abundance of 99.64%.

In this study, the team members developed two tripeptide alanine (Alanine tripeptide) microcrystalline sample which respectively had parallel formula β- sheet and antiparallel β- sheet structure. They used 1 mg of the sample to conduct 14N / 14N-related NMR method. It was found that only in alanine tripeptide with antiparallel β- sheet structure, 14N / 14N-related signal could be detected in the space of the β-strand. This also proves that the method can identify the type of parallel β-sheet and antiparallel β- sheet. Flarebio provides you with superior recombinant proteins such as recombinant Nrg2 at good prices.

Researchers identify new mechanism of tuberculosis infection

Researchers at UT Southwestern Medical Center have discovered a new way of tuberculosis bacteria entering human body, revealing the potential treatment. One of the world's most deadly diseases, tuberculosis - mainly lung disease, has infected 8 million people and results in 1.5 million deaths each year. Scientists have conducted many studies using recombinant proteins including recombinant horse proteins.

A new study published online in Cell Report determines another way of bacteria entering the body, which may have a significant impact on the development of new therapies for prevention of tuberculosis infection.

Research team led by Dr. Michael Shiloh found that the micro-folding cells (M-cell) transmission is a new, unknown mechanism of Mtb entering human body. M-cell is specialized airway epithelial cell, and its role is to transport particles from the compartment of lower airway mucosal cell surface. Shiloh said, "Our research shows that once inhaling Mtb bacteria, they can also directly enter the body through the connection airway tissues of M-cell and then go to the lymph nodes. This is a key finding, indicating that it is possible that the disease attacks outside alveolar macrophages and the pathogenesis of tuberculosis infection are also very important."

Dr. Shiloh who are interested in producing different recombinant proteins such as recombinant dog proteins said that this M-cell mediated Mtb mechanism may help explain an ancient disease called lymphatic system. In this disease, tuberculosis infection rarely occurs in the lungs but causes cervical lymph node disease.

Although further research is needed, the potential clinical applications found by the team will help to develop methods or drugs which prevent Mtb from entering M-cells. For example, Dr. Shiloh said that to prevent Mtb from attack receptors on the surface of M-cells such as vaccinating anti-bacteria protein - can be prevent bacteria from entering, infecting and spreading to other organs.

Dr. Shiloh and his team are currently working to find out M-cell receptor in human cell surface which involve in Mtb bacteria transmission and the exact mechanism by making bacteria on the surface of cells transfer to the bottom. "We are conducting a number of experimental methods to determine Mtb genes and proteins are involved in this process." The lead author and postdoctoral researcher in internal medicine Dr. Nair said.

Flarebio Biotech LLC is a National High-Tech Enterprise with research, production and sales as one. Our main business includes recombinant proteins (including recombinant Nrg2), antibodies and ELISA kits.

Scientists find new phosphatase inhibitor with higher selectivity and lower polarity

Phosphatase is a regulatory protein which is as important as kinase, and its function is opposite to kinase, so it can be seen as an endogenous kinase inhibitor. The main obstacle of the development of phosphatase inhibitors is selectivity and through-membrane. Phosphatase substrate is a phosphorylated protein, and its activity pocket is mainly bond to phosphate, so high-polarity reactive ligand is very great and the selectivity is very poor. While when the polarity is too great, it can't reach the target location through the cell membrane. Poor selectivity is difficult to be used to accurately study the biological function of phosphatase. The most famous phosphatase is undoubtedly the target for diabetes PTP1B. There are also many phosphatase recombinant proteins in the market.

Many kinases and phosphatases themselves are in an inactive state (usually the combination of regulatory domain and catalytic domain of protein molecules prevents the combination of substrate and catalytic domain), and they require a certain signal to change conformation to be activated. Clotting proteins in an inactive state, namely the protein glue reported by the media, is not a new concept. The first kinase inhibitor drugs Geli Wei which is a non-active conformation combination with ABL. Recombinant proteins such as recombinant horse proteins are used in the development stage. But for phosphatase, it is indeed the first one.

Their screening method is very interesting. The researchers used a peptide known to activate SHP2 to activate half of the SHP2 and left half of the enzyme which was not activated in order to maintain a dynamic equilibrium which was easily broken and to increase the chances of finding a weak lead compound. Then the researchers used the whole protein and catalytic domain to respectively screen a relatively small compound library, so they can only select the allosteric inhibitor. If the compound inhibits the catalytic domain and the entire protein fragment at the same time, then it showed it conducts inhibition by binding with active pocket. The researchers found a sign compound of 12uM, and they found this lead compound with in-vivo activity through a simple optimization. By expressing SHP2 which lost allosteric binding ability but still had catalytic function, researchers showed convincingly that this compound indeed played the role through SHP2. The crystal structure also proved binding mechanism.

The highlights of this work is filtering mode. They only screened 100,000 compounds to find a good lead compound. The activity of lead compound may be not outstanding, but its through-membrane and selectivity is much better than the previous phosphatase inhibitors. If the other phosphatases are also screened in this way of hundreds of millions of DNA encoded chemical libraries, they should find a lot of similar nature phosphatase inhibitors. If the phosphatase inhibitors with high activity, high selectivity and through-membrane can be easier to be found, phosphatases might become the next popular target. Flarebio provides recombinant proteins such as recombinant Nrg2 with good quality.